SACT 1
Alternative Names: SACT-1Latest Information Update: 27 Jun 2023
At a glance
- Originator Aptorum Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Cell death stimulants; Proto-oncogene protein c-myc translation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Neuroblastoma
- Preclinical Cancer; Colorectal cancer; Triple negative breast cancer
Most Recent Events
- 22 Jun 2023 Aptorum Group submits the relevant phase Ib/IIa clinical trial protocol of SACT-1 for the treatment of neuroblastoma to US FDA
- 05 Jun 2023 Aptorum Group plans to submit an IND application with the US FDA in USA for Neuroblastoma for phase Ib/IIa (PO) in 2025
- 05 Jun 2023 Aptorum Group plans a phase Ib/IIa trial for neuroblastoma in 2023